Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-11-03

FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved a supplemental application for doxorubicin hydrochloride from BluePoint Laboratories, adding a new approved generic version of the cancer chemother…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)

Snippet

SUPPL AP for DOXORUBICIN HYDROCHLORIDE (DOXORUBICIN HYDROCHLORIDE)